BioSpace News Archive

Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.

A silicon wafer offers the powerful insights of the human genome for the low price of $100. Ultima Genomics CEO Gilad Almogy discussed the therapeutic possibilities with BioSpace.

Sanofi and Swedish Orphan Biovitrum AB presented for the first time , in a late-breaking session at the 30thInternational Society on Thrombosis and Haemostasis Congress, positive results from the XTEND-1 pivotal Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa, an investigational factor VIII replacement therapy, in previously treated adults and adolescents ≥12 years with severe hemophilia A.

Positive data from the Phase 3 ATLAS-PPX study evaluating the efficacy and safety of once-monthly fitusiran in adults and adolescents with severe hemophilia A or B who were previously treated with prior factor or bypassing agent prophylaxis were presented in a late-breaking session at the International Society on Thrombosis and Haemostasis 2022 Congress.

Telix Pharmaceuticals Limited is pleased to announce that Kevin Richardson, a senior global executive with a career focus on sales, marketing and business operations in the oncology and radiopharmaceutical markets, will commence in the role of CEO, Telix Americas, on 11 July 2022.

Pliant Therapeutics, Inc., announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis.

Freeline Therapeutics Holdings plc announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 dose-confirmation B-LIEVE trial for FLT180a, the company’s AAVS3-based gene therapy candidate for people with hemophilia B, at the International Society on Thrombosis and Haemostasis Congress being held in London, July 9-13, 2022.

Telix Pharmaceuticals Limited announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON of its investigational renal cancer imaging agent TLX250-CDx.